| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6414cf0912e2737a41f574e3435772e3 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-02 |
| filingDate |
2020-09-29^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffe13c9cfb2f3fc5b4eba97594e18cea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_466822aa14635449d9dcad133ff11e15 |
| publicationDate |
2021-04-16^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202114663-A |
| titleOfInvention |
A use of a combination of an ezh2 inhibitor and a fusion protein containing a tgf-β receptor in preparation of medicine for treating tumors |
| abstract |
The present invention relates to a use of a combination of an EZH2 inhibitor and a fusion protein containing a TGF-[beta] receptor in preparation of medicine for treating tumors. Specifically, the EZH2 inhibitor related to the present invention is selected from a compound shown in a formula (I) or pharmaceutically acceptable salts thereof. The combination of the EZH2 inhibitor and the TGF-[beta] receptor fusion protein further enhances anti-tumor effects compared with single drug. |
| priorityDate |
2019-09-30^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |